|
Durham, NC — Male Contraceptive Initiative (MCI), a 501(c)(3) non-profit, has awarded $320,000 to DesireLine to support a new market research study assessing consumer demand for next-generation male contraceptive options across five major European markets. This study will evaluate men’s interest in using novel male birth control and identify which product features matter most to potential users and their partners – evidence that can inform product design, positioning, investment, and future access strategies in Europe. “Europe is a critical next frontier for male contraception. By testing real product profiles with men and partners across the EU5, we’ll generate decision-ready evidence on who is most likely to adopt which options, and the product features that will make uptake real.” – Steve Kretschmer, Executive Director, DesireLine Building on strong global evidence of demand The new European research builds on a prior multi-country study co-funded by MCI and the Gates Foundation that surveyed 12,435 men across six LMICs (plus 3,243 men in the United States, with a post-Dobbs follow-up of 3,070 men). That prior research found strong latent demand: an average of 61% of men reported interest in trying a novel male contraceptive within the first year of availability, ranging from 39-49% in the United States (pre-/post-Dobbs) to 76% in Nigeria and Bangladesh. The same study also showed that how a method is administered and when it is used are major drivers of men’s preferences—, pointing to the importance of aligning product design with convenience and real-world routines. New study will focus on EU5 markets and real product candidates The newly funded study will focus on five major European markets, the United Kingdom, Germany, France, Italy, and Spain, to generate actionable insights in high-income settings where demand data remain limited. Using a web-based survey with ~15,000 respondents (~3,000 men per country), the research will assess interest in multiple fixed profiles of leading product candidates currently in development, including:
The study will also examine barriers to adoption, partner dynamics, and willingness to pay, producing cross-country comparisons and user segmentation (“who wants what, and why”) to support stakeholders across R&D, funding, advocacy, and policy. Why the research matters By providing robust, Europe-specific evidence on likely uptake and preferred attributes for emerging male contraceptive options, the study aims to help de-risk development and accelerate progress toward expanding contraceptive choice and shared responsibility in family planning. “Demand evidence helps de-risk development. This study will deliver Europe-specific insights on what men and couples value most so product developers, funders, and advocates can accelerate more safe, reversible options and move closer to shared responsibility in contraception.” – Heather Vahdat, MPH, Executive Director, Male Contraceptive Initiative About Male Contraceptive Initiative (MCI):
Male Contraceptive Initiative’s vision is “Reproduction Autonomy for All” and works to accomplish this by bringing new male contraceptives to market. The non-profit accomplishes this through direct funding, technical support, research, and advocacy. MCI believes that couples deserve options and that they offer the biggest potential impact by focusing on male contraceptives. It’s time men are given more opportunities to contribute toward family planning. To learn more, please visit: https://www.malecontraceptive.org/ About DesireLine: DesireLine is a strategy and management consultancy that helps governments, development partners, and private-sector innovators design and execute demand-responsive, investment-ready strategies and programs. The firm brings commercial-sector rigor, combining evidence generation, behavioral and data sciences, and human-centered design, to support scalable, sustainable impact across Africa, Asia, and global institutions. Media Contact: Sabey Boswell Associate Director Male Contraceptive Initiative [email protected]
0 Comments
Leave a Reply. |
RSS Feed